Testosterone is an ally of macrophages in the battle against adrenal cancers

Pinterest LinkedIn Tumblr +

Why are cancers of the adrenal glands more common among women?

Why are prognoses worse for them?

A team of scientists led by a CNRS researcher answers these questions in an article published on 14 October 2022 in Science Advances.

They demonstrate that, in male mice, there is greater recruitment of immune cells known as macrophages, which can eliminate tumour cells.

LISTEN TO EPISODE 3 WITH AINSLEY CAMPBELL AND MIKE FIELD

Hence, aggressive tumour progression is scarcely seen in male mice; while in female miles, macrophages do not slow the growth of tumours, which eventually metastasise.

Through molecular analyses, the team determined that recruitment of tumour-fighting macrophages depends on testosterone.

After simple administration of the hormone to females, macrophages able to eradicate tumour cells were rallied to battle.

THE FUTURE IS FUSIONS PODCAST WITH CRAIG UNDERHILL AND MALINDA ITCHINS: NTRK FUSIONS IN NSCLC AND CRC

On the basis of these findings, the scientists conducted another study using data on humans, which revealed the same difference in macrophage recruitment rates between men and women with adrenal cancers.

This discovery suggests the potential of hormonal stimulation as a treatment for this type of cancer, whose five-year survival rate is less than 30%.


Source: Centre national de la recherche scientifique

Share.

About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.